Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

190

Full text

154

Free full text

Publication Types

Journal Article

190

Review

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Observational Study

Multicenter Study

Systematic Review

Clinical Trial

Case Reports

Comparative Study

Clinical Trial, Phase III

Meta-Analysis

Clinical Trial, Phase II

Research Support, N.I.H., Extramural

Controlled Clinical Trial

Consensus Development Conference

Clinical Trial, Phase I

Practice Guideline

Letter

Research Support, U.S. Gov't, P.H.S.

Historical Article

Network Meta-Analysis

Scoping Review

Editorial

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2004

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Denosumab""[mesh_terms]

192 Results

Searching titles within these results

Monoclonal antibodies for treatment of osteoporosis.

Jan Rosa, Vladimir Palicka, Kveta Kroupova

Drugs of today (Barcelona, Spain : 1998) 2023;59(3):195-204

Full Text

Abstract

Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.

Athanasios Siolos, Thomas Zaramboukas, Argyrios Doumas, Alexandra Terzaki, Spyridon Karras, Apostolos Goropoulos, Themistoklis Tzotzas, Stelios Tigas

Hormones (Athens, Greece) 2022;21(1):171-176

Full Text

Abstract

Persistence of denosumab in Slovak patients with bone metastases - a prospective observational study.

M Porubská, A Němcová

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2023;36(1):54-64

Full Text

Abstract

Treatment of Hypercalcemia of Malignancy.

Ghada El-Hajj Fuleihan, Marlene Chakhtoura

Endocrinology and metabolism clinics of North America 2022;50(4):781-792

Full Text

Abstract

Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.

Richard H de Boer, Jeffrey Goh, Amanda Goldrick, Yoland C Antill, Kenneth Pittman

Asia-Pacific journal of clinical oncology 2017;13(4):266-276

Full Text

Abstract

Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.

Athanasios D Anastasilakis, Polyzois Makras, Antonis Kattamis, Eva Kassi, Efthimia Rigatou, Symeon Tournis, Ploutarchos Tzoulis, Maria P Yavropoulou

Acta bio-medica : Atenei Parmensis 2022;93(5):e2022305

Free Full Text

Abstract

Hypercalcemia of Malignancy.

Mimi I Hu

Endocrinology and metabolism clinics of North America 2022;50(4):721-728

Full Text

Abstract

Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism.

Yihan Zhao, Qian Ren, Linong Ji, Fang Zhang, Simin Zhang, Xueyao Han, Xiaona Zhang, Leili Gao

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2024;56(12):839-844

Free Full Text

Abstract

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

Daniela Niepel, Bertrand Tombal, Roger von Moos, Jean-Jacques Body

BMC urology 2018;18(1):81

Free Full Text

Abstract

A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.

Mohammad Hassan Murad, Matthew T Drake, Ghada El-Hajj Fuleihan, Zhen Wang, Larry J Prokop, Magdoleen H Farah, Noora S Rajjoub, Sahrish H Shah, Ahmed Mushannen, Samer Saadi, Mohammed Firwana, Bashar Hasan, Tarek Nayfeh, Mohamed O Seisa

The Journal of clinical endocrinology and metabolism 2023;108(3):585-591

Full Text

Abstract

Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.

Peter A Kopp, Gerasimos P Sykiotis, Massimo Bongiovanni, Heba Alwan, Abdallah Roukain

Frontiers in endocrinology 2022;12():794988

Free Full Text

Abstract

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment.

Arkadi Chines, Joop P van den Bergh, Kenneth G Saag, Shuang Huang, Klaus Engelke, Roland Chapurlat, Beatriz Oliveri, Eric Lespessailles, Osvaldo D Messina, Bert van Rietbergen, Melissa Sam Bevers, Piet Geusens

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022;37(6):1136-1146

Free Full Text

Abstract

Current and future treatments of secondary osteoporosis.

Adolfo Diez-Perez, Xavier Nogués, Sabina Herrera, Raquel Soriano

Best practice & research. Clinical endocrinology & metabolism 2015;28(6):885-94

Full Text

Abstract

Denosumab for Prevention of Acute Onset Immobilization-Induced Alterations of Bone Turnover: A Randomized Controlled Trial.

Andrea Reinprecht, Maria Butylina, Lisa Irina Wadiura, Katharina Kerschan-Schindl, Marie-Bernadette Aretin, Peter Pietschmann, Andreas Gleiss, Mario Mischkulnig

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022;37(11):2156-2164

Free Full Text

Abstract

Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.

Akinori Sakai, Naoki Sawa, Yoshifumi Ubara, Rikako Hiramatsu

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021;36(10):1900-1907

Full Text

Abstract

Results: 1 – 15 / 192

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Denosumab""[mesh_terms]

Monoclonal antibodies for treatment of osteoporosis.

Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.

Persistence of denosumab in Slovak patients with bone metastases - a prospective observational study.

Treatment of Hypercalcemia of Malignancy.

Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.

Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.

Hypercalcemia of Malignancy.

Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism.

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.

Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment.

Current and future treatments of secondary osteoporosis.

Denosumab for Prevention of Acute Onset Immobilization-Induced Alterations of Bone Turnover: A Randomized Controlled Trial.

Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.

Results for
""Denosumab""[mesh_terms]